Zhang X, Huang Z, Wang J, Ma Z, Yang J, Corey E, et al. Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling. Cancers (Basel). 2021;13: pubmed publisher

Lenting K, van den Heuvel C, van Ewijk A, Elmelik D, de Boer R, Tindall E, et al. Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing. Acta Neuropathol Commun. 2019;7:185 pubmed publisher

Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik A, et al. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3. Oncogene. 2018;37:2313-2325 pubmed publisher

White M, Lin C, Rajapakshe K, Dong J, Shi Y, Tsouko E, et al. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer. Mol Cancer Res. 2017;15:1017-1028 pubmed publisher

Frank S, Berger P, Ljungman M, Miranti C. Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC. J Cell Sci. 2017;130:1952-1964 pubmed publisher

Ashkenazi A, Bento C, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, et al. Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature. 2017;545:108-111 pubmed publisher

Polanco M, Parodi S, Piol D, Stack C, Chivet M, Contestabile A, et al. Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Sci Transl Med. 2016;8:370ra181 pubmed publisher

Depaolo J, Wang Z, Guo J, Zhang G, Qian C, Zhang H, et al. Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis. Oncotarget. 2016;7:71417-71428 pubmed publisher

Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, et al. αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res. 2016;76:5163-74 pubmed publisher

Bott L, Salomons F, Maric D, Liu Y, Merry D, Fischbeck K, et al. The polyglutamine-expanded androgen receptor responsible for spinal and bulbar muscular atrophy inhibits the APC/C(Cdh1) ubiquitin ligase complex. Sci Rep. 2016;6:27703 pubmed publisher

Kaushik A, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, et al. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016;7:11612 pubmed publisher

Mounir Z, Korn J, Westerling T, Lin F, Kirby C, Schirle M, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. elife. 2016;5: pubmed publisher

Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, et al. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget. 2016;7:69397-69411 pubmed publisher

Johnson D, Hooker E, Luong R, Yu E, He Y, Gonzalgo M, et al. Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice. PLoS ONE. 2016;11:e0148851 pubmed publisher

Mehraein Ghomi F, Church D, Schreiber C, Weichmann A, Basu H, Wilding G. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes Cancer. 2015;6:428-44 pubmed

Hagberg Thulin M, Nilsson M, Thulin P, Céraline J, Ohlsson C, Damber J, et al. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. Mol Cell Endocrinol. 2016;422:182-191 pubmed publisher

Qiu M, Fan Q, Zhu Z, Kwan S, Chen L, Chen J, et al. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget. 2015;6:31702-20 pubmed publisher

Liu X, Chen X, Rycaj K, Chao H, Deng Q, Jeter C, et al. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget. 2015;6:23959-86 pubmed

Chen S, Okada M, Nakato R, Izumi K, Bando M, Shirahige K. The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin. J Biol Chem. 2015;290:21713-23 pubmed publisher

Sun F, Indran I, Zhang Z, Tan M, Li Y, Lim Z, et al. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. Carcinogenesis. 2015;36:757-68 pubmed publisher

Lee S, Luong R, Johnson D, Cunha G, Rivina L, Gonzalgo M, et al. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis. Oncogene. 2016;35:702-14 pubmed publisher

Toropainen S, Malinen M, Kaikkonen S, Rytinki M, Jääskeläinen T, Sahu B, et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 2015;43:848-61 pubmed publisher

Wosnitzer M, Mielnik A, Dabaja A, Robinson B, Schlegel P, Paduch D. Ubiquitin Specific Protease 26 (USP26) expression analysis in human testicular and extragonadal tissues indicates diverse action of USP26 in cell differentiation and tumorigenesis. PLoS ONE. 2014;9:e98638 pubmed publisher

Qiu M, Bao W, Wang J, Yang T, He X, Liao Y, et al. FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer. BMC Cancer. 2014;14:78 pubmed publisher

Samaan S, Tranchevent L, Dardenne E, Polay Espinoza M, Zonta E, Germann S, et al. The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways. Nucleic Acids Res. 2014;42:2197-207 pubmed publisher

Ni M, Chen Y, Fei T, Li D, Lim E, Liu X, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27:734-48 pubmed publisher

Sarkar S, Brautigan D, Parsons S, Larner J. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene. 2014;33:26-33 pubmed publisher

Hsu F, Yang M, Lin E, Tseng C, Lin H. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells. Am J Physiol Endocrinol Metab. 2011;300:E902-8 pubmed publisher

Zhang D, Hu Q, Liu X, Ji Y, Chao H, Liu Y, et al. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2020;11:2089 pubmed publisher

Wang J, Yu Q, Qiu Z, Dai T, Wang S, Yang X, et al. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion. Aging (Albany NY). 2020;12:397-415 pubmed publisher

Georgescu C, Corbin J, Thibivilliers S, Webb Z, Zhao Y, Koster J, et al. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. BMC Cancer. 2019;19:423 pubmed publisher

Kounatidou E, Nakjang S, McCracken S, Dehm S, Robson C, Jones D, et al. A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Res. 2019;47:5634-5647 pubmed publisher

Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X, et al. A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene. 2019;38:4977-4989 pubmed publisher

Cato L, De Tribolet Hardy J, Lee I, Rottenberg J, Coleman I, Melchers D, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019;35:401-413.e6 pubmed publisher

Rosati R, Patki M, Chari V, Dakshnamurthy S, McFall T, Saxton J, et al. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth. J Biol Chem. 2016;291:25983-25998 pubmed

Uo T, Dvinge H, Sprenger C, Bradley R, Nelson P, Plymate S. Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene. 2017;36:1440-1450 pubmed publisher

Hay C, Hunter I, Mackenzie A, McEwan I. An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells. PLoS ONE. 2015;10:e0139990 pubmed publisher

Chan S, Selth L, Li Y, Nyquist M, Miao L, Bradner J, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015;43:5880-97 pubmed publisher

Hay C, Watt K, Hunter I, Lavery D, Mackenzie A, McEwan I. Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR. Horm Cancer. 2014;5:299-311 pubmed publisher

Jin H, Zhao J, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun. 2014;5:3972 pubmed publisher

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz C, Evans C, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198-3210 pubmed publisher

Rico Bautista E, Zhu W, Kitada S, Ganapathy S, Lau E, Krajewski S, et al. Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling. Oncotarget. 2013;4:1212-29 pubmed

Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, et al. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate. 2013;73:1352-63 pubmed publisher

Tomasicchio M, Avenant C, Du Toit A, Ray R, Hapgood J. The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor. PLoS ONE. 2013;8:e62895 pubmed publisher

Patki M, Chari V, Sivakumaran S, Gonit M, Trumbly R, Ratnam M. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem. 2013;288:11047-65 pubmed publisher

Zhang Z, Sun Y, Cho Y, Chow C, Simons S. PA1 protein, a new competitive decelerator acting at more than one step to impede glucocorticoid receptor-mediated transactivation. J Biol Chem. 2013;288:42-58 pubmed publisher

Olson B, Johnson L, McNeel D. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013;62:585-96 pubmed publisher

La Montagna R, Caligiuri I, Maranta P, Lucchetti C, Esposito L, Paggi M, et al. Androgen receptor serine 81 mediates Pin1 interaction and activity. Cell Cycle. 2012;11:3415-20 pubmed publisher

Cherian M, Wilson E, Shapiro D. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem. 2012;287:23368-80 pubmed publisher

Chan S, Li Y, Dehm S. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012;287:19736-49 pubmed publisher

Schayek H, Bentov I, Jacob Hirsch J, Yeung C, Khanna C, Helman L, et al. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Horm Metab Res. 2012;44:511-9 pubmed publisher

Hay C, McEwan I. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS ONE. 2012;7:e32514 pubmed publisher

Garay J, Karakas B, Abukhdeir A, Cosgrove D, Gustin J, Higgins M, et al. The growth response to androgen receptor signaling in ER?-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012;14:R27 pubmed

Li X, Zhu C, Tu W, Yang N, Qin H, Sun Z. ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract. PLoS ONE. 2011;6:e25040 pubmed publisher

Rytinki M, Kaikkonen S, Sutinen P, Palvimo J. Analysis of androgen receptor SUMOylation. Methods Mol Biol. 2011;776:183-97 pubmed publisher

Zhu C, Luong R, Zhuo M, Johnson D, McKenney J, Cunha G, et al. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J Biol Chem. 2011;286:33478-88 pubmed publisher

Bruno R, Vasaitis T, Gediya L, Purushottamachar P, Godbole A, Ates Alagoz Z, et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 2011;76:1268-79 pubmed publisher

Vieira J, Saraiva K, Barbosa M, Porto R, Cresto J, Peixoto C, et al. Effect of dexamethasone and testosterone treatment on the regulation of insulin-degrading enzyme and cellular changes in ventral rat prostate after castration. Int J Exp Pathol. 2011;92:272-80 pubmed publisher

Aubé M, Larochelle C, Ayotte P. Differential effects of a complex organochlorine mixture on the proliferation of breast cancer cell lines. Environ Res. 2011;111:337-47 pubmed publisher

Cai J, Hong Y, Weng C, Tan C, Imperato McGinley J, Zhu Y. Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol. 2011;300:H1210-21 pubmed publisher

Altintas D, Vlaeminck V, Angelov D, Dimitrov S, Samarut J. Cell cycle regulated expression of NCoR might control cyclic expression of androgen responsive genes in an immortalized prostate cell line. Mol Cell Endocrinol. 2011;332:149-62 pubmed publisher

Schayek H, Bentov I, Sun S, Plymate S, Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res. 2010;316:1479-88 pubmed publisher

Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010;464:792-6 pubmed publisher

Zielinski A, Fong S, Allison J, Kawahara M, Coppe J, Feiler H, et al. The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. Int J Cancer. 2010;126:2490-6 pubmed publisher

Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci. 2009;100:2028-33 pubmed publisher

Zhang X, Fournier M, Ware J, Bissell M, Yacoub A, Zehner Z. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther. 2009;8:499-508 pubmed publisher

Xu B, Sun Y, Tang G, Xu C, Wang L, Zhang Y, et al. Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor. Cancer Lett. 2009;278:220-229 pubmed publisher

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya L, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther. 2008;7:2348-57 pubmed publisher

Li H, Xu L, Masuda K, Raymundo E, McLeod D, Dobi A, et al. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem. 2008;283:28988-95 pubmed publisher

Tam C, Chan K, Liu V, Pang B, Yao K, Shiu S. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res. 2008;45:403-12 pubmed publisher

Guarino G, Spampinato S. Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells. Neuroreport. 2008;19:1131-5 pubmed publisher

Purushottamachar P, Khandelwal A, Vasaitis T, Bruno R, Gediya L, Njar V. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorg Med Chem. 2008;16:3519-29 pubmed publisher

Serda R, Bisoffi M, Thompson T, Ji M, Omdahl J, Sillerud L. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate. 2008;68:773-83 pubmed publisher

Alimirah F, Panchanathan R, Chen J, Zhang X, Ho S, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia. 2007;9:1152-9 pubmed

Plymate S, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res. 2007;13:6429-39 pubmed

Arima T, Enokida H, Kubo H, Kagara I, Matsuda R, Toki K, et al. Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci. 2007;98:1720-6 pubmed

Tyson D, Inokuchi J, Tsunoda T, Lau A, Ornstein D. Culture requirements of prostatic epithelial cell lines for acinar morphogenesis and lumen formation in vitro: role of extracellular calcium. Prostate. 2007;67:1601-13 pubmed

Monsef N, Helczynski L, Lundwall A, Påhlman S. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. Prostate. 2007;67:1219-29 pubmed

Palazzolo I, Burnett B, Young J, Brenne P, La Spada A, Fischbeck K, et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet. 2007;16:1593-603 pubmed

Klokk T, Kurys P, Elbi C, Nagaich A, Hendarwanto A, Slagsvold T, et al. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol. 2007;27:1823-43 pubmed

Kim K, Dobi A, Shaheduzzaman S, Gao C, Masuda K, Li H, et al. Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase. Prostate Cancer Prostatic Dis. 2007;10:30-8 pubmed

Mukhopadhyay N, Ferdinand A, Mukhopadhyay L, Cinar B, Lutchman M, Richie J, et al. Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp Cell Res. 2006;312:3782-95 pubmed

Yin H, Radomska H, Tenen D, Glass J. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line. BMC Cancer. 2006;6:158 pubmed

Sobel R, Wang Y, Sadar M. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In Vitro Cell Dev Biol Anim. 2006;42:33-9 pubmed

Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006;580:2294-300 pubmed

Alimirah F, Chen J, Xin H, Choubey D. Androgen receptor auto-regulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett. 2006;580:1659-64 pubmed

Tokar E, Ancrile B, Cunha G, Webber M. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation. 2005;73:463-73 pubmed

Bernard D, Gil J, Dumont P, Rizzo S, Monte D, Quatannens B, et al. The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. Oncogene. 2006;25:1358-66 pubmed

Basrawala Z, Alimirah F, Xin H, Mohideen N, Campbell S, Flanigan R, et al. Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene. 2006;25:2812-7 pubmed

Ilagan R, Zhang L, Pottratz J, Le K, Salas S, Iyer M, et al. Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther. 2005;4:1662-9 pubmed

Ray M, Wafa L, Cheng H, Snoek R, Fazli L, Gleave M, et al. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer. 2006;118:1108-19 pubmed

Tokar E, Webber M. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis. 2005;22:265-73 pubmed

Li W, Cavasotto C, Cardozo T, Ha S, Dang T, Taneja S, et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol. 2005;19:2273-82 pubmed

Gu Y, Kim K, Ko D, Srivastava S, Moul J, McLeod D, et al. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res. 2005;25:1-8 pubmed